These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 27441452)

  • 21. A Randomized Trial of Contingency Management for Smoking Cessation During Intensive Outpatient Alcohol Treatment.
    Cooney JL; Cooper S; Grant C; Sevarino K; Krishnan-Sarin S; Gutierrez IA; Cooney NL
    J Subst Abuse Treat; 2017 Jan; 72():89-96. PubMed ID: 27542442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
    Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined pharmacotherapy and behavioural interventions for smoking cessation.
    Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Oct; 10():CD008286. PubMed ID: 23076944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Smoking Cessation Treatment for Patients With Mental Disorders Using CBT and Combined Pharmacotherapy.
    Loreto AR; Carvalho CFC; Frallonardo FP; Ismael F; Andrade AG; Castaldelli-Maia JM
    J Dual Diagn; 2017; 13(4):238-246. PubMed ID: 28489501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of motivational lung age feedback on short-term quit rates in smokers seeking intensive group treatment: A randomized controlled pilot study.
    Foulds J; Veldheer S; Hrabovsky S; Yingst J; Sciamanna C; Chen G; Maccani JZ; Berg A
    Drug Alcohol Depend; 2015 Aug; 153():271-7. PubMed ID: 26051163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
    MacLean KA; Johnson MW; Griffiths RR
    J Psychopharmacol; 2011 Nov; 25(11):1453-61. PubMed ID: 21956378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychedelic Psychiatry's Brave New World.
    Nutt D; Erritzoe D; Carhart-Harris R
    Cell; 2020 Apr; 181(1):24-28. PubMed ID: 32243793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.
    Thomas K; Malcolm B; Lastra D
    J Psychoactive Drugs; 2017; 49(5):446-455. PubMed ID: 28481178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Smoking quit rates among patients receiving pharmacist-provided pharmacotherapy and telephonic smoking cessation counseling.
    Augustine JM; Taylor AM; Pelger M; Schiefer D; Warholak TL
    J Am Pharm Assoc (2003); 2016; 56(2):129-36. PubMed ID: 27000162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
    Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
    Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tobacco cessation interventions for young people.
    Grimshaw GM; Stanton A
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003289. PubMed ID: 17054164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
    Ross S; Bossis A; Guss J; Agin-Liebes G; Malone T; Cohen B; Mennenga SE; Belser A; Kalliontzi K; Babb J; Su Z; Corby P; Schmidt BL
    J Psychopharmacol; 2016 Dec; 30(12):1165-1180. PubMed ID: 27909164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.
    Barrett FS; Carbonaro TM; Hurwitz E; Johnson MW; Griffiths RR
    Psychopharmacology (Berl); 2018 Oct; 235(10):2915-2927. PubMed ID: 30062577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit.
    Polosa R; Caponnetto P; Maglia M; Morjaria JB; Russo C
    BMC Public Health; 2014 Nov; 14():1159. PubMed ID: 25380748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.